14 February 2019

Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, today announces that it will host its first European Key Opinion Leader (KOL) Advisory Panel meeting ahead of the 21st Congress of the ESSM on 14-16 February 2019, at Cultural and Congress Centre Cankarjev Dom, Ljubljana, Slovenia. This meeting follows the successful US KOL Advisory Panel meeting at the Sexual Medicine Society of North America (SMSNA) in November 2018.

As announced on 28 January 2019, Tim Holland, Director of Clinical Development at Futura Medical, will be presenting safety data in female partners on its lead product MED2005, a topical glyceryl trinitrate ("GTN") gel for the treatment of erectile dysfunction ("ED") at the ESSM. The poster entitled "Establishing the safety profile in sexual partners of a new topical glyceryl trinitrate gel for the treatment of erectile dysfunction" on Thursday 14 February at 15.30 CET. The presentation will be part of the "Male sexual dysfunction: medical treatment" poster session held in Foyer 1, Floor 1.

Professor David Ralph, world leading expert in erectile dysfunction and male infertility and member of the Futura European KOL Advisory Panel, spoke with Futura Medical’s Executive Director and Head of R&D, Ken James about the unmet need and innovation in the treatment of ED. A link to the video can be found here.

David is a Consultant Urologist at University College London and the Institute of Urology,and Former President of the Andrology Section of the British Association of Urological Surgeons (BAUS); the British Society for Sexual Medicine (BSSM) and the ESSM.

James Barder, Chief Executive Officer of Futura Medical said: "I would like to thank Professor Ralph for his support and involvement in Futura’s first R&D Day, which took place in London on Monday 11 February 2019. The event was well received and provided an opportunity to hear first-hand from a prominent KOL on the significant negative effect ED has on the quality of life, relationships and overall wellbeing of ED sufferers and their partners. The event also provided an opportunity for the Futura team to describe the Company’s R&D strategy with a focus on its DermaSys® drug delivery technology and lead product MED2005. We look forward to hosting our second Advisory Panel meeting to further our discussions on the on-going development and educational programme for MED2005 with a number of eminent European Key Opinion Leaders."

 

For further information please contact:

Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
+44 (0) 1483 685 670
investor.relations@futuramedical.com
www.futuramedical.com

Nominated Adviser:
N+1 Singer
Aubrey Powell/ Ben Farrow (Corporate Finance)
Tom Salvesen/ Mia Gardner (Corporate Broking)
Tel: +44 (0) 20 7496 3000

For media enquiries please contact:

Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Ellie Blackwell
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144

 

Notes to editors:

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

About MED2005: Eroxon® - Topical treatment for erectile dysfunction (ED)

MED2005, which uses Futura’s DermaSys® drug delivery system, is the development name for its topical glyceryl trinitrate ("GTN") gel. It has the potential to be a highly differentiated therapy for the treatment of men with ED, especially mild to moderate ED. MED2005’s rapid onset of action means that it has the potential to become the world’s fastest-acting treatment for ED, with a speed of onset of around five minutes. Viagra® and Cialis® which dominate the existing on-market ED therapies are taken orally and do not take effect for at least 30 minutes and typically one hour or more2. Speed of onset and method of administration of MED2005 also help restore spontaneity and intimacy. Importantly, MED2005 may also be appropriate for ED sufferers on nitrates and other drugs that are contraindicated for use with phosphodiesterase-5-inhibitors ("PDE5Is") such as Viagra® and Cialis® and other existing oral ED treatments.

Note 1: Sources, Shabsigh R et al, J Urol 2005; vol. 174, 662-667
EMEA & Withdrawal assessment report for Viagra, 2008
Note 2: US patient information for Viagra® and Cialis®